The Phase 2a study EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blinded, placebo-controlled study to evaluate the safety and tolerability of exidavnemab and its pharmacokinetic profile.

The results of the study, Otitis Treatment with OtoSight™ – Modification of Antibiotic Treatment Intervention in Children (OTO-MATIC), have been published via open access in the International Journal of Pediatric Otorhinolaryngology.

Published in Cell Metabolism, the Phenomix and Mayo Clinic research shows the MyPhenomeTM test can help providers guide obesity treatment by matching patients to GLP-1s or phentermine/topiramate based on their unique biology.

Initial FIH procedures launch FastWave’s multi-center feasibility study evaluating the safety and performance of its laser-based coronary IVL platform.

Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period.